Skip to main content

Table 3 Survival rates

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

 all patientspatients receiving systemic therapy onlypatients receiving surgical intervention
 n = 32n = 23n = 9
PFS median (range)3.1 (0.6–16.2)2.8 (0.6–16.2)4.7 (2.1–11.9)
OS median (range)4.6 (1.6–17.5)3.9 (1.6–17.5)7.4 (3.3–16.6)
  1. PFS progression free survival; OS overall survival